Female Urology/URPS
10 cases on first-line overactive bladder therapy and the anticholinergic-dementia signal, vaginal estrogen for recurrent UTI prevention in a breast-cancer survivor on an aromatase inhibitor, methenamine versus a patient's own stone-prevention chemistry, duloxetine for stress incontinence across two regulators' opposite conclusions, botulinum toxin versus sacral neuromodulation, stopping pentosan polysulfate after a retinal finding, sex-specific desmopressin dosing for nocturia, off-label alpha-blockade after a sling, preoperative vaginal estrogen before prolapse surgery, and ospemifene for genitourinary syndrome of menopause — choose a case below to open its full multi-voice debate.
Two patients share the same first prescribing decision for overactive bladder — but one variable, present in only one of them, changes which risk actually deserves to drive the choice.
Two women, the same recurrent infections, the same proposed treatment — but one of them has a second physician in the room whose specialty reads the safety data on its own, different terms.
A real non-inferiority trial makes the antibiotic-sparing case. Her own chronic stone-prevention regimen makes the chemistry case against it, in exactly the same patient.
The same drug, the same trial data, and two regulators who looked at it and reached opposite conclusions — leaving a US clinician to decide what an off-label prescription actually means here.
Two third-line therapies with comparable efficacy in the largest trial that's ever compared them — until a detail in her own hands makes one of their harms far more costly to her than the trial's average patient.
Twelve years of a drug that never worked especially well, now flagged for a retinal risk that may already be doing its damage regardless of what happens today.
The drug's own sex-specific dosing exists because women are more vulnerable to its central risk — which makes the demographic most likely to be offered it also the one where every other risk factor happens to stack in the same direction.
A drug approved for a gland she doesn't have, tried because nothing else exists — while the surgical fix she might still need becomes harder to perform for every week the trial continues.
A biopsy-level finding that the tissue really does improve, set against a bothered patient counting the weeks until her bulge symptoms are actually addressed.
The two therapies guidelines prefer both require an act her body won't tolerate, leaving an oral option whose warning label was written for an entire drug class, not for her.